JAZZJazz Pharmaceuticals plc
What is the market doing?
No clear lean: rangebound and insiders net selling (often routine).
Choppy, but holding above its 200-day average. Oversold (RSI 20). Price is +5% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Heavily shorted, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How JAZZ is trading
Jazz Pharmaceuticals plc is +70% over the past year while the S&P 500 is +18%: 52 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +4.9%
vs 200-day average · close to trend
- RSI (14)
- 20
RSI (14) · oversold, sold harder than it has been bought
- Below its 52-week high
- 17%
Below its 52-week high
Details›
- Last close2026-10-09
- $218.41
- 1 monthS&P 500 +2.7%
- −9.2%
- 1 yearS&P 500 +18%
- +70%
- 5 yearsS&P 500 +88%
- +62%
- vs 50-day average$244.57
- −11%
- 52-week high
- $261.72
- 52-week low
- $127.00
- Annualised volatility
- 36%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- −$2.8M
| Year | Return |
|---|---|
| 2026 (year to date) | +28% |
| 2025 | +38% |
| 2024 | +0.12% |
| 2023 | −23% |
| 2022 | +25% |
| 2021 | −23% |
| 2020 | +11% |
| 2019 | +20% |
| 2018 | −7.9% |
| 2017 | +23% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 5 of 10 | +1.7% |
| Feb | 10 | 5 of 10 | +2.4% |
| Mar | 10 | 6 of 10 | +0.54% |
| Apr | 10 | 6 of 10 | +0.43% |
| May | 10 | 4 of 10 | +0.44% |
| Jun | 10 | 5 of 10 | +1.1% |
| Jul | 11 | 7 of 11 | +2.5% |
| Aug | 11 | 4 of 11 | −0.42% |
| Sep | 11 | 2 of 11 | −3.0% |
| Oct | 11 | 4 of 11 | −1.3% |
| Nov | 10 | 4 of 10 | +3.8% |
| Dec | 10 | 6 of 10 | +0.91% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.